Evaluation of clinical efficacy of stereotactic body radiotherapy combined with chemotherapy for locally advanced pancreatic cancer
10.3760/cma.j.cn341190-20240505-00505
- VernacularTitle:体部立体定向放疗联合化疗治疗局部晚期胰腺癌的临床疗效评价
- Author:
Qian WANG
1
;
Yating WANG
;
Yunlong WU
Author Information
1. 渭南市中心医院普通外科，渭南 714000
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Radiotherapy;
Drug therapy;
CA-19-9 antigen;
Carcinoembryonic antigen;
Drug-related side effects and adverse reactions
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(3):359-363
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of stereotactic body radiotherapy combined with chemotherapy in the treatment of patients with locally advanced pancreatic cancer.Methods:This study is a prospective randomized controlled study that included 80 patients with locally advanced pancreatic cancer admitted to Weinan Central Hospital from January 2020 to June 2022. Patients were randomly divided into two groups using a drawing lots method: the control group ( n = 40) received chemotherapy and conventional medication, while the observation group ( n = 40) received stereotactic body radiotherapy in addition to the treatments in the control group. Each patient was followed up for 1 year. The local control rate of pancreatic cancer, levels of serum carbohydrate antigen 19-9 and carcinoembryonic antigen, abdominal pain relief rate, jaundice resolution rate, incidence of adverse reactions, and 1-year survival rate were compared between the two groups. Results:The local control rate in the observation group reached 85.00% (34/40), which was significantly higher than that in the control group ( χ2 = 5.23, P < 0.05). After treatment, the levels of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in the observation group were significantly lower than those in the control group ( χ2 = 2.60, 3.97, both P < 0.001). The 1-year survival rate in the observation group was 65.00% (26/40), which was significantly higher than that in the control group [42.50% (17/40), χ2 = 4.07, P < 0.05). However, there was no significant difference in incidence of adverse reactions between the two groups ( χ2 = 2.58, 0.05, 0.39, 2.05, all P > 0.05). Conclusions:Stereotactic body radiotherapy combined with chemotherapy has shown good therapeutic effects in patients with locally advanced pancreatic cancer, without significantly increasing the risk of adverse reactions. Therefore, this combination treatment regimen can be considered an effective option for the treatment of locally advanced pancreatic cancer.
